Age, Risk Factors for CVD and Cognitive Functioning - Full Text View

Purpose

To relate cardiovascular disease (CHD) risk factors to cognitive performance among middle-aged and elderly men and women over a 10 year longitudinal study period.

Condition

Cardiovascular Diseases
Heart Diseases
Neurologic Manifestations

MedlinePlus related topics:

Heart Diseases

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:	February 2000
Estimated Study Completion Date:	January 2004

Detailed Description:

BACKGROUND:

The Framingham Heart Study is a major epidemiological investigation of prospective relationships between risk factors for the development of cardiovascular disease (CVD risk factors) and CVD risk factor outcomes. The Framingham Study and other large, prospective studies have resulted in an extensive literature on the impact of CVD risk factors (including age) and CVD outcomes. Comparatively, there have been many fewer studies of the impact of CVD risk factors on cognitive functioning, and possibly no studies of the effect of objectively measured, competing risk factors on cognitive functioning.

DESIGN NARRATIVE:

Dr. Elias and colleagues used cardiovascular risk factor data from the Framingham Heart Study (N= 2,123) in a prospective design allowing them to relate CVD risk factors (including age and gender) to two outcome measures: (1) level of cognitive performance and (2) change in cognitive performance over a 10 year longitudinal study period. The overall goals were to determine the best multivariate combination of biological and psychosocial risk factors for the prediction of lowered cognitive ability in middle-aged and elderly men and women, and to evaluate the relative impact of age, gender, and other biological and psychosocial risk factors on cognitive functioning.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

No eligibility criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00007397

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators


Investigator:	Merrill Elias	Boston University

More Information

Publications:

Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. 2003 Feb;27(2):260-8.

Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, Seshadri S, DeCarli C, Wolf PA. Framingham Stroke Risk Profile and Lowered Cognitive Performance. Stroke. 2004 Jan 15 [Epub ahead of print]

Elias PK, Elias MF, D'Agostino RB, Sullivan LM, Wolf PA. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med. 2005 Jan-Feb;67(1):24-30.

Study ID Numbers:	958
First Received:	December 19, 2000
Last Updated:	December 21, 2005
ClinicalTrials.gov Identifier:	NCT00007397
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Signs and Symptoms

Heart Diseases

Neurologic Manifestations

Additional relevant MeSH terms:

Nervous System Diseases

Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00007397